Focus on 5 Growth areas - Sales, Volume, Profits, Margins, Market Share.
2/n
Should be on Top 3 players in its respective market.
If not, is the company capturing market share from the incumbents with the launch of unique or niche products, entering new markets, new brands, patents etc ?
Is the company Asset light or Asset heavy ?
3/n
History of Equity dilution ? Is the company a frequent dilutor of equity ?
Will the future growth come from Debt, Equity dilution or both ?
And how does it change the leverage position of the company ?
4/n
Minimum Govt interference.
Can the company shift the burden to customers ?
On the other hand, if the company get benefits from the govt, how sustainable is it ?
Is it one off events like anti-dumping duty or a long term change like benefiting low income housing loans.
5/n
Is the size of the industry is large or small? Is it saturated or growing.
A smallcap which is a market leader in its niche segment with honest management is on its way of being a multibagger.
6/n
Management compensation as % of Net Profit. Is it linked to performance or flat structure ? Is it in par with the competitors ?
Is the company professional managed or Owners Managed ?
Key man risk ?
7/n
Its true that not every honest management is hunger for growth. There are many examples whose managements are very honest but they are not in growth race.
Where does this management fits in ?
8/n
Its a challenge for a Debt free company with a decent management to go bankrupt.
Hence we prefer debt free companies. But we do consider D/E of less than 0.4 with Interest Coverage ratio of well above 3.
9/n
Growth coming back to Quality is a deadly combination.
Example: Bata, Jubilant Foods, Nestle, Titan
Watchout for the management changes OR growth triggers in Quality companies.
10/n
How management handles Free Cash Flows ? Give back as dividends, Continues Capex, Diversification, Acqusitions ?
Government can privatize PSUs. But can't privatize the Babus culture.
11/n
What is driving the growth ?
Innovation, New geographies, New Products, Distribution, Cross selling ?
More importance of Revenue growth over PAT growth. PAT growth can be obtained internally, but Revenue growth has to come from external sources.
12/n
Track record of revenue growth over the last 3,5,7,10 years period ?
Is last 5Y sales CAGR > 10Y sales CAGR ?
What is the catalyst ? Same with PAT growth as well.
13/n
Practicability of the management guidance.
What are the hurdles in the growth trajectory ?
Probabilistic approach.
Feasability:
- Constraint of Net block / fixed assets
- Management capabilities
- Cash in hands
- Demand for sales
What can go wrong in the plan ?
14/n
Have a look at
- Tax evasions,
- Dividend track record,
- High Promoter holding,
- Pledge,
- Related party transactions,
- Too many subsidiaries,
- CFO & PAT comparision historical trend.
15/n
Where doesn your company fits into:
Great Mgmt + Great Sector
Great Mgmt + Cyclical / Dying Sector
Doubtful Mgmt + Great Sector
Doubtful Mgmt + Cyclical / Dying Sector
Once can make money on all 4, but high chances of giving it all back & a little more in the last 3.
16/n
Is Margins expanding & Why ?
- Low Raw material costs (not sustainable)
- Operating Leverage (sustainable)
- Financial Leverage (sustainable)
- New High margin product launches (sustainable)
17/n
Risk Management more of an Art than a Science.
It is easy to quantify risk using mathematical model. But we can't ignore the power of human heartbeat when we actually face it.
Risk is a fate rather than a choice.
Without numbers, risk is a matter of Gut.
18/n
The greatest advantage of gambling comes from not playing it.
Its sometimes hard to find a cause where there seems to be none. Market Gurus understand it the least.
Risk per unit of Stress - An important concept to be internalized while selecting a company.
19/n
More often than not, Averaging Up is a good Risk Management strategy than Averaging down.
No investment stretegy can explain buying DHFL / Manpasand now as they are still trading, other than being plain stupid or being a self proclaimed punter or both.
20/n
Is the company enjoying any Tax shield, Deffered Tax Laibility or Deffered Tax Asset or operating from a SEZ ?
Trend in Debtor days, Creditor days, Inventory period, Asset turnover.
21/n
Is the company running on positive or negative working capital ? If Receivables as % of Total Revenue > 40% - it is a Big Red flag.
High Debt, High Receivables, Low Marin business - A Ticking Time Bomb.
Is the comp funding dividends via Debt ? Best example - Tata Motors
22/n
Nothing can be more important than ROE. But at the same time ROE is not so relevant for cyclical businesses and holdings companies.
Dupoint Analysis to find triggers in Return on Equity:
Is the Return on Captial more than Cost of Capital ?
Asset turnover ratio should be looked in accordance with PAT Margins.
24/n
A low margin business but with high asset turn is better than a high margin business with a low asset turn. Because in later case most of the capital is get locked up in Receivables, Fixed assets, Inventory etc.
25/n
These are few points which we look out when we start analyzing a company.
Why looking at past 10 years record and investing in such large cap proven stocks is not great method.
Sometimes coffee may not smell right. These are largest global companies in 2000. Gave great 2 decades run from 1980. Now it's 20 years. Return frm 2000 is "ZERO".
Thread
By the time Welch stepped down in 2001, he had transformed GE from a $25 billion manufacturing company into a $130 billion conglomerate of “boundary-less” segments.
Dividend history tll 2000. It went global, shutting down unrelated businesses. Jack Welch books are best ones to read if you are company manager or factory owner.
Thread - Laurus labs earnings call (not a buying recommendation)
• Richmore lifesciences will help to enter in recombinant protein. • Revenue from formulation div is 35%. • Recently got approval for anti-retroviral drug and have orders for the same and will service in first half of fy22. • Seen growth in North America and Europe
• Commenced marketing of in-life science products, 2 out of 5 products are launched, remaining in next 6 months. • For EU validated additional products for CDMO with partners and expect significant upside in fy23. • Capacity through de-bottlenecking is operational now
Revenue expected to grow in double digits in constant currency for FY’22. EBIT margin expected to be between 19.0% and 21.0% for FY’22. Management has indicated that around 100 bps of margin impact in FY22 will be on account of investment in new geography.
The consensus EBIT margin expectation in FY22 21.2% as such will see some downgrade in earning or around 3-5%
Ingrevia—a union of ‘Ingre’ denoting ingredients and ‘vie’ in French meaning life (i.e., ingredients for
life). Operating under three segments -- specialty chemicals, nutrition & health solutions and life
science chemicals
JIL offers more than 350 products to more than 1,400 customers globally.